Your browser doesn't support javascript.
loading
Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer.
Criscitiello, C; Vingiani, A; Maisonneuve, P; Viale, G; Viale, G; Curigliano, G.
Afiliação
  • Criscitiello C; Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy. carmen.criscitiello@ieo.it.
  • Vingiani A; Pathology Department, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Maisonneuve P; Division of Epidemiology and Biostatistics, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Viale G; Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
  • Viale G; Pathology Department, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Curigliano G; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Breast Cancer Res Treat ; 183(2): 347-354, 2020 Sep.
Article em En | MEDLINE | ID: mdl-32621251

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores Tumorais / Linfócitos do Interstício Tumoral / Quimioterapia Adjuvante / Receptor ErbB-2 / Receptor alfa de Estrogênio Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores Tumorais / Linfócitos do Interstício Tumoral / Quimioterapia Adjuvante / Receptor ErbB-2 / Receptor alfa de Estrogênio Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article